Literature DB >> 27087893

Comment: Fundamentals and Innovation in Antibiotic Trials.

Scott R Evans1, Dean Follmann2.   

Abstract

Entities:  

Year:  2015        PMID： 27087893      PMCID： PMC4831648          DOI： 10.1080/19466315.2015.1094406

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN： 1946-6315            Impact factor:   1.452


× No keyword cloud information.
  22 in total

1.  Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics.

Authors:  Ralph B D'Agostino; Joseph M Massaro; Lisa M Sullivan
Journal:  Stat Med       Date:  2003-01-30       Impact factor: 2.373

2.  Sample size and the ethics of non-inferiority trials.

Authors:  John H Powers; Charles K Cooper; Daphne Lin; David B Ross
Journal:  Lancet       Date:  2005 Jul 2-8       Impact factor: 79.321

3.  Key issues in end point selection for heart failure trials: composite end points.

Authors:  James D Neaton; Gerry Gray; Bram D Zuckerman; Marvin A Konstam
Journal:  J Card Fail       Date:  2005-10       Impact factor: 5.712

4.  Assessing non-inferiority: a combination approach.

Authors:  Ping Gao; James H Ware
Journal:  Stat Med       Date:  2008-02-10       Impact factor: 2.373

5.  Effectiveness and safety of colistin: prospective comparative cohort study.

Authors:  Mical Paul; Jihad Bishara; Ariela Levcovich; Michal Chowers; Elad Goldberg; Pierre Singer; Shaul Lev; Perla Leon; Maria Raskin; Dafna Yahav; Leonard Leibovici
Journal:  J Antimicrob Chemother       Date:  2010-03-18       Impact factor: 5.790

6.  Evaluating Ebola therapies--the case for RCTs.

Authors:  Edward Cox; Luciana Borio; Robert Temple
Journal:  N Engl J Med       Date:  2014-12-03       Impact factor: 91.245

7.  Editorial Commentary: A Chance to Change the Paradigm of Outcome Assessment of Antimicrobial Stewardship Programs.

Authors:  Jose Molina; Jose M Cisneros
Journal:  Clin Infect Dis       Date:  2015-06-25       Impact factor: 9.079

Review 8.  Head-to-head randomized trials are mostly industry sponsored and almost always favor the industry sponsor.

Authors:  Maria Elena Flacco; Lamberto Manzoli; Stefania Boccia; Lorenzo Capasso; Katina Aleksovska; Annalisa Rosso; Giacomo Scaioli; Corrado De Vito; Roberta Siliquini; Paolo Villari; John P A Ioannidis
Journal:  J Clin Epidemiol       Date:  2015-02-07       Impact factor: 6.437

9.  Neurotoxic and nephrotoxic effects of colistin in patients with renal disease.

Authors:  E Wolinsky; J D Hines
Journal:  N Engl J Med       Date:  1962-04-12       Impact factor: 91.245

10.  Deaths attributable to carbapenem-resistant Enterobacteriaceae infections.

Authors:  Matthew E Falagas; Giannoula S Tansarli; Drosos E Karageorgopoulos; Konstantinos Z Vardakas
Journal:  Emerg Infect Dis       Date:  2014-07       Impact factor: 6.883
View more
  8 in total

1.  Evaluating Anti-Infective Drugs in the Resistant Pathogen Setting: Can we Use External Controls?

Authors:  Scott R Evans; John Powers
Journal:  Stat Commun Infect Dis       Date:  2017-03-14

2.  Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection.

Authors:  Sarah B Doernberg; Thuy Tien Tram Tran; Steven Y C Tong; Mical Paul; Dafna Yahav; Joshua S Davis; Leonard Leibovici; Helen W Boucher; G Ralph Corey; Sara E Cosgrove; Henry F Chambers; Vance G Fowler; Scott R Evans; Thomas L Holland
Journal:  Clin Infect Dis       Date:  2019-05-02       Impact factor: 9.079

Review 3.  Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.

Authors:  Sarah B Doernberg; Thomas P Lodise; Joshua T Thaden; Jose M Munita; Sara E Cosgrove; Cesar A Arias; Helen W Boucher; G Ralph Corey; Franklin D Lowy; Barbara Murray; Loren G Miller; Thomas L Holland
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

4.  Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group.

Authors:  Jacqueline Huvane; Lauren Komarow; Carol Hill; Thuy Tien T Tran; Carol Pereira; Susan L Rosenkranz; Matt Finnemeyer; Michelle Earley; Hongyu Jeanne Jiang; Rui Wang; Judith Lok; Scott R Evans
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

5.  Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step toward Pragmatism in Benefit:risk Evaluation.

Authors:  Scott R Evans; Dean Follmann
Journal:  Stat Biopharm Res       Date:  2016-12-06       Impact factor: 1.452

6.  Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.

Authors:  David van Duin; Judith J Lok; Michelle Earley; Eric Cober; Sandra S Richter; Federico Perez; Robert A Salata; Robert C Kalayjian; Richard R Watkins; Yohei Doi; Keith S Kaye; Vance G Fowler; David L Paterson; Robert A Bonomo; Scott Evans
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

7.  Totality of outcomes: A different paradigm in assessing interventions for treatment of tuberculosis.

Authors:  Grace Montepiedra; Courtney M Yuen; Michael L Rich; Scott R Evans
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2016-08

8.  Introduction and geographic availability of new antibiotics approved between 1999 and 2014.

Authors:  Cecilia Kållberg; Christine Årdal; Hege Salvesen Blix; Eili Klein; Elena M Martinez; Morten Lindbæk; Kevin Outterson; John-Arne Røttingen; Ramanan Laxminarayan
Journal:  PLoS One       Date:  2018-10-16       Impact factor: 3.240
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.